Stockysis — AI-Powered Stock News & Sentiment Analysis

OptimizeRx Lowers FY2026 Sales Guidance from $118.000M-$124.000M to $109.000M-$114.000M

Benzinga Newsdesk www.benzinga.com Negative 95.3%

Neg 95.3% Neu 0% Pos 0%

OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.

Comments

No comments yet. Be the first!